Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Exploring strengths and limits of urinary D-chiro inositol phosphoglycans (IPG-P) as a screening test for preeclampsia: A systematic review and meta-analysis.

Scioscia M, Noventa M, Cavallin F, Straface G, Pontrelli G, Fattizzi N, Libera M, Rademacher TW, Robillard PY.

J Reprod Immunol. 2019 Jul 26;134-135:21-27. doi: 10.1016/j.jri.2019.07.005. [Epub ahead of print] Review.

PMID:
31382126
2.

New insights into early and late onset subgroups of preeclampsia from longitudinal versus cross-sectional analysis of urinary inositol-phosphoglycan P-Type.

L'Omelette AD, Dawonauth L, Rademacher L, Robillard PY, Scioscia M, Jankee S, Lee Kwai Yan MY, Razgia JB, Rademacher TW.

J Reprod Immunol. 2018 Feb;125:64-71. doi: 10.1016/j.jri.2017.11.006. Epub 2017 Dec 6.

PMID:
29253795
3.

Putative Key Role of Inositol Messengers in Endothelial Cells in Preeclampsia.

Kunjara S, McLean P, Rademacher L, Rademacher TW, Fascilla F, Bettocchi S, Scioscia M.

Int J Endocrinol. 2016;2016:7695648. Epub 2016 Sep 21. Review.

4.

Urinary inositol phosphoglycan-P type: near patient test to detect preeclampsia prior to clinical onset of the disease. A study on 416 pregnant Mauritian women.

Dawonauth L, Rademacher L, L'Omelette AD, Jankee S, Lee Kwai Yan MY, Jeeawoody RB, Rademacher TW.

J Reprod Immunol. 2014 Mar;101-102:148-152. doi: 10.1016/j.jri.2013.06.001. Epub 2013 Aug 2.

PMID:
23962712
5.

L15. Biological aspects of inositol phosphoglycans in human pregnancy and preeclampsia.

Scioscia M, Fratelli N, Musola M, Burton GJ, Rademacher TW.

Pregnancy Hypertens. 2011 Jul-Oct;1(3-4):247-8. doi: 10.1016/j.preghy.2011.08.016. Epub 2011 Sep 29. No abstract available.

PMID:
26009046
6.

Inositol phosphoglycans and preeclampsia: from bench to bedside.

Scioscia M, Williams PJ, Gumaa K, Fratelli N, Zorzi C, Rademacher TW.

J Reprod Immunol. 2011 May;89(2):173-7. doi: 10.1016/j.jri.2011.03.001. Epub 2011 May 6. Review.

PMID:
21549431
7.

Endometrial secretions: creating a stimulatory microenvironment within the human early placenta and implications for the aetiopathogenesis of preeclampsia.

Burton GJ, Scioscia M, Rademacher TW.

J Reprod Immunol. 2011 May;89(2):118-25. doi: 10.1016/j.jri.2011.02.005. Epub 2011 Apr 29. Review.

PMID:
21531028
8.

Inositol phosphoglycan P-type in infants of preeclamptic mothers.

Scioscia M, Robillard PY, Hall DR, Rademacher LH, Williams PJ, Rademacher TW.

J Matern Fetal Neonatal Med. 2012 Feb;25(2):193-5. doi: 10.3109/14767058.2011.557789. Epub 2011 Mar 14.

PMID:
21401313
9.

Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder.

Paine MA, Scioscia M, Williams PJ, Gumaa K, Rodeck CH, Rademacher TW.

Hypertens Pregnancy. 2010;29(4):375-84. doi: 10.3109/10641950903242667.

PMID:
20701477
10.

Age-related changes in the response of rat adipocytes to insulin: evidence for a critical role for inositol phosphoglycans and cAMP.

Kunjara S, Greenbaum AL, Rademacher TW, McLean P.

Biogerontology. 2010 Aug;11(4):483-93. doi: 10.1007/s10522-010-9271-x. Epub 2010 Mar 25.

PMID:
20336370
11.

The link between insulin resistance and preeclampsia: new perspectives.

Scioscia M, Gumaa K, Rademacher TW.

J Reprod Immunol. 2009 Nov;82(2):100-5. doi: 10.1016/j.jri.2009.04.009. Epub 2009 Jul 22. Review.

PMID:
19628283
12.

Increased inositol phosphoglycan P-type in the second trimester in pregnant women with type 2 and gestational diabetes mellitus.

Scioscia M, Gumaa K, Selvaggi LE, Rodeck CH, Rademacher TW.

J Perinat Med. 2009;37(5):469-71. doi: 10.1515/JPM.2009.082.

PMID:
19492925
13.

Is there a link between insulin resistance and inflammatory activation in preeclampsia?

Scioscia M, Greco P, Selvaggi LE, Rademacher TW.

Med Hypotheses. 2009 Nov;73(5):813-7. doi: 10.1016/j.mehy.2009.01.057. Epub 2009 May 13.

PMID:
19443128
14.

Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by "push-pull" system.

McLean P, Kunjara S, Greenbaum AL, Gumaa K, López-Prados J, Martin-Lomas M, Rademacher TW.

J Biol Chem. 2008 Nov 28;283(48):33428-36. doi: 10.1074/jbc.M801781200. Epub 2008 Sep 3.

15.

Release of inositol phosphoglycan P-type by the human placenta following insulin stimulus: a multiple comparison between preeclampsia, intrauterine growth restriction, and gestational hypertension.

Scioscia M, Paine MA, Gumaa K, Rodeck CH, Rademacher TW.

J Matern Fetal Neonatal Med. 2008 Aug;21(8):581-5. doi: 10.1080/14767050802199934.

PMID:
18609357
16.

Insight into the role of inositol phosphoglycans in insulin response and the regulation of glucose and lipid metabolism illustrated by the response of adipocytes from two strains of rats.

Kunjara S, McLean P, Greenbaum AL, Rademacher TW.

Mol Genet Metab. 2008 Jun;94(2):263-6. doi: 10.1016/j.ymgme.2008.02.006. Epub 2008 Mar 21.

PMID:
18359258
17.

Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitus.

Scioscia M, Kunjara S, Gumaa K, McLean P, Rodeck CH, Rademacher TW.

Diabet Med. 2007 Nov;24(11):1300-4.

PMID:
17956457
18.

Altered urinary release of inositol phosphoglycan A-type in women with gestational diabetes mellitus.

Scioscia M, Kunjara S, Gumaa K, Gomez Galan AM, McLean P, Rodeck CH, Rademacher TW.

Gynecol Obstet Invest. 2007;64(4):217-23. Epub 2007 Jul 30.

PMID:
17664885
19.

Preeclampsia, insulin signalling and immunological dysfunction: a fetal, maternal or placental disorder?

Rademacher TW, Gumaa K, Scioscia M.

J Reprod Immunol. 2007 Dec;76(1-2):78-84. Epub 2007 May 29. Review.

PMID:
17537518
20.

Inositol phosphoglycan P-type in healthy and preeclamptic pregnancies.

Scioscia M, Gumaa K, Whitten M, Selvaggi LE, Rodeck CH, Rademacher TW.

J Reprod Immunol. 2007 Dec;76(1-2):85-90. Epub 2007 May 9. Review.

PMID:
17493685
21.

Inositol phosphoglycan P-type in preeclampsia: a novel marker?

Williams PJ, Gumaa K, Scioscia M, Redman CW, Rademacher TW.

Hypertension. 2007 Jan;49(1):84-9. Epub 2006 Nov 20.

PMID:
17116762
22.

Inositol phosphoglycan putative insulin mediator in human amniotic fluid.

Scioscia M, Vimercati A, Selvaggi LE, Rodeck CH, Rademacher TW.

J Matern Fetal Neonatal Med. 2006 Jan;19(1):9-12.

PMID:
16492584
23.

P-type inositol phosphoglycans in serum and amniotic fluid in active pre-eclampsia.

Paine MA, Scioscia M, Gumaa KA, Rodeck CH, Rademacher TW.

J Reprod Immunol. 2006 Apr;69(2):165-79. Epub 2005 Dec 27.

PMID:
16384607
24.

Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2.

Scioscia M, Gumaa K, Kunjara S, Paine MA, Selvaggi LE, Rodeck CH, Rademacher TW.

J Clin Endocrinol Metab. 2006 Feb;91(2):709-17. Epub 2005 Dec 6.

PMID:
16332940
25.

Improvement of glucose homeostasis in obese diabetic db/db mice given Plasmodium yoelii glycosylphosphatidylinositols.

Elased KM, Gumaa KA, de Souza JB, Playfair JH, Rademacher TW.

Metabolism. 2004 Aug;53(8):1048-53.

PMID:
15281017
26.

Genetic regulation of mouse glycosylphosphatidylinositol-phospholipase D.

Flores-Borja F, Kieszkievicz J, Church V, Francis-West PH, Schofield J, Rademacher TW, Lund T.

Biochimie. 2004 Apr-May;86(4-5):275-82.

PMID:
15194230
27.
28.

Possible involvement of inositol phosphoglycan-P in human parturition.

Paine MA, Rodeck CH, Williams PJ, Rademacher TW.

J Reprod Immunol. 2003 Aug;59(2):267-75.

PMID:
12896828
29.

Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells.

Kvirkvelia N, Vojnovic I, Warner TD, Athie-Morales V, Free P, Rayment N, Chain BM, Rademacher TW, Lund T, Roitt IM, Delves PJ.

Clin Exp Immunol. 2002 Feb;127(2):263-9.

30.

Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats.

Schofield JN, Stephens JW, Hurel SJ, Bell KM, deSouza JB, Rademacher TW.

Mol Genet Metab. 2002 Feb;75(2):154-61.

PMID:
11855934
31.

Reversal of type 2 diabetes in mice by products of malaria parasites. II. Role of inositol phosphoglycans (IPGs).

Elased KM, Gumaa KA, de Souza JB, Rahmoune H, Playfair JH, Rademacher TW.

Mol Genet Metab. 2001 Jul;73(3):248-58.

PMID:
11461192
32.

Inositolphosphoglycan mediators structurally related to glycosyl phosphatidylinositol anchors: synthesis, structure and biological activity.

Martín-Lomas M, Khiar N, García S, Koessler JL, Nieto PM, Rademacher TW.

Chemistry. 2000 Oct 2;6(19):3608-21.

PMID:
11072827
33.

Structure and expression of the human glycosylphosphatidylinositol phospholipase D1 (GPLD1) gene.

Schofield JN, Rademacher TW.

Biochim Biophys Acta. 2000 Nov 15;1494(1-2):189-94.

PMID:
11072085
34.
35.
36.

Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes.

Kunjara S, Wang DY, Greenbaum AL, McLean P, Kurtz A, Rademacher TW.

Mol Genet Metab. 1999 Dec;68(4):488-502.

PMID:
10607479
37.

Correlation between IgG anti-type II collagen levels and arthritic severity in murine arthritis.

Williams PJ, Jones RH, Rademacher TW.

Autoimmunity. 1998;27(4):201-7.

PMID:
9623497
38.

Recent advances in glycoconjugate analysis and glycobiology.

Rademacher TW.

Curr Opin Biotechnol. 1998 Feb;9(1):74-9. Review.

PMID:
9503591
39.

Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver.

Caro HN, Kunjara S, Rademacher TW, León Y, Jones DR, Avila MA, Varela-Nieto I.

Biochem Mol Med. 1997 Aug;61(2):214-28.

PMID:
9259987
40.
41.

Bias in murine IgG isotype immobilisation. Implications for IgG glycoform analysis ELISA procedures.

Jones RH, Rademacher TW, Williams PJ.

J Immunol Methods. 1996 Oct 16;197(1-2):109-20.

PMID:
8890898
42.

Analysis of murine IgG isotype galactosylation in collagen-induced arthritis.

Williams PJ, Rademacher TW.

Scand J Immunol. 1996 Oct;44(4):381-7.

PMID:
8845032
43.

Structural similarities among malaria toxins insulin second messengers, and bacterial endotoxin.

Caro HN, Sheikh NA, Taverne J, Playfair JH, Rademacher TW.

Infect Immun. 1996 Aug;64(8):3438-41.

45.

Malaria: a tumour necrosis factor inhibitor from parasitized erythrocytes.

Sheikh NA, Caro HN, Taverne J, Playfair JH, Rademacher TW.

Immunology. 1996 Mar;87(3):461-6.

46.

Short communication: selective placental transport of maternal IgG to the fetus.

Williams PJ, Arkwright PD, Rudd P, Scragg IG, Edge CJ, Wormald MR, Rademacher TW.

Placenta. 1995 Dec;16(8):749-56.

PMID:
8710805
47.

Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis.

Rademacher TW, Jones RH, Williams PJ.

Adv Exp Med Biol. 1995;376:193-204. Review. No abstract available.

PMID:
8597248
48.

Agalactosyl glycoforms of IgG autoantibodies are pathogenic.

Rademacher TW, Williams P, Dwek RA.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6123-7.

49.

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, et al.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5602-6.

50.

Supplemental Content

Loading ...
Support Center